Merck receives FDA approval for cholesterol pill Lipfendra
Merck announced on Thursday that the U.S. Food and Drug Administration has approved its cholesterol pill, Lipfendra, marking the first oral PCSK9 inhibitor to gain regulatory approval, reports BritPanorama.
This approval comes at a pivotal moment for Merck, which is diversifying its portfolio as its blockbuster cancer treatment, Keytruda, is set to face patent expirations starting in 2028. The introduction of Lipfendra is part of the company’s strategy to address the high prevalence of cholesterol-related health issues.
Lipfendra is designed to treat patients with hypercholesterolemia, characterized by elevated levels of low-density lipoprotein (LDL) cholesterol, commonly known as “bad” cholesterol. This condition can lead to significant cardiovascular complications, including plaque buildup in the arteries.
With its once-daily dosage, Lipfendra offers a new treatment alternative to the current market, dominated by injectable PCSK9 inhibitors. It works by blocking the PCSK9 protein, a key player in cholesterol regulation, which contrasts with traditional oral statins that inhibit liver cholesterol production.
According to the American Heart Association, approximately one in four adults in the U.S. has high LDL cholesterol levels. The FDA’s decision was informed by two late-stage trials showing substantial reductions in LDL cholesterol among diverse patient groups, including those diagnosed with familial hypercholesterolemia and individuals already on statins.
The approval could reshape the landscape of cholesterol treatments, currently led by injectables like Amgen’s Repatha and Regeneron and Sanofi’s Praluent. Analysts, including Scotiabank’s Louise Chen, have projected that Lipfendra may achieve peak sales potential in the tens of billions.
Furthermore, the approval was expedited under the FDA commissioner’s National Priority Voucher program, aimed at shortening review times for drugs deemed essential for public health or national security. As pharmaceutical innovation moves forward, the impact of Lipfendra on both patient care and Merck’s market strategy remains to be seen.
